Effects of Honeysuckle (Lonicera maackii) Management on Avian Abundance

Amur honeysuckle (Lonicera maackii) is an invasive shrub that is found in many parts of Ohio and grows well in Ohio's forest ecosystems. This study attempted to assess the effect of treating Amur honeysuckle on avian abundance within Germantown MetroPark in Germantown, Ohio. The honeysuckle was chemically treated with a foliar glyphosate spray and left to break down naturally. The birds were grouped into three different guilds: ground nesting species, shrub nesting species, and fruit eating species. In addition to the effects of treatment, the important vegetation characteristics, such as honeysuckle and native shrub densities, percent forb or grass cover on the plots, basal area, and percent canopy cover within in the plots were also measured and compared among treatment courses for each guild. Overall, there was very little effect on treatment on bird abundance within the species guilds, either positively or negatively. There were some differences between the different treatment courses but that was likely due to inherent differences in the plots making up those courses. Vegetation characteristics of plots were more important in determining avian abundance. There is a time gap between honeysuckle treatment and the desired results. How the treatment of invasive species effects native species of birds is important because it can help to preserve threatened species or assist managers in making habitat management decisions.Five Rivers MetroParksNo embargoAcademic Major: Forestry, Fisheries, and Wildlif

Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer

Introduction. Orally administered preparations from the Trametes versicolor (Tv) mushroom have been hypothesized to improve immune response in women with breast cancer after standard chemotherapy and radiotherapy. Methods. A phase I, two-center, dose escalation study was done to determine the maximum tolerated dose of a Tv preparation when taken daily in divided doses for 6 weeks after recent completion of radiotherapy. Eleven participants were recruited and nine women completed the study. Each cohort was comprised of three participants given one of three doses of Tv (3, 6, or 9 grams). Immune data was collected pre- and postradiation, at 3 on-treatment time points and after a 3-week washout. Results. Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated. Immunological results indicated trends in (1) increased lymphocyte counts at 6 and 9 grams/day; (2) increased natural killer cell functional activity at 6 grams/day; (3) dose-related increases in CD8+ T cells and CD19+ B cells , but not CD4+ T cells or CD16+56+ NK cells. Conclusion. These findings show that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the postprimary treatment setting. This Tv preparation may improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment

The Ursinus Weekly, December 10, 1951

Feulner goes to convention in New York • Supply Store announces 40 percent reductions • Pi Gamma Mu sets initiation banquet for new members • Booster Committee doing art work • Messiah concert called credit to Philip\u27s directing ability • Harte and Lukens named \u2753 year book co-editors • Count to speak at 3rd Forum on January 9 • Y hears lecture on loyalty oath • Students dance at winter whirl • Inge Rudloff to speak • Pre-Christmas week of gay events arrives • Curtain Club may give play again • Candlelight Communion planned Thursday night • St. Nick furthers his education by paying visit to Ursinus College • Editorials: Christmas spirit; Thanks for paint job; New religion discovered • English dorm life described as much different from U.S. • I\u27m dreaming of a tight Christmas • Christmas spirits rise as caroling day draws near • Investment in dinner at Millers\u27 home pays high dividends • Bruin court squad scores 67-61 win over Lycoming team in extra period • Snell\u27s Belles practice for coming court season • Intramural basketball to start after Xmas vacation • Temple Pharmacy defeated by locals as 1951-52 basketball season begins • Twenty-seven report to Coach Kuhrt Wieneke for wrestling • Crusaders\u27 rally dies as Bears win thriller, 60-58 • French Club holds annual holiday soiree • Teacher to address FTA • Jones reads Galsworthy • Chest reaches half mark • Chess Club scores loss to Lansdale teamhttps://digitalcommons.ursinus.edu/weekly/1530/thumbnail.jp

Is Sex Important to Marital Satisfaction or is Marital Satisfaction Important to Sex? Top-down and Bottom-up Processing in the Bedroom.

How do people determine satisfaction in their relationships? One way may be to engage in bottom-up processing and rely on sexual satisfaction to arrive at an overall evaluation of the relationship. Another way may be to engage in top-down processing and allow the overall relationship satisfaction to color the perceptions of sexual satisfaction. The current study more rigorously examined the causal relationship between sexual and marital satisfaction through multilevel cross-lagged regression analyses of 8 waves of marital and sexual satisfaction reported by 72 newlywed couples over the first five years of marriage. Consistent with bottom-up processing, initial sexual satisfaction predicted subsequent marital satisfaction. Also, consistent with top-down processing, initial marital satisfaction predicted subsequent sexual satisfaction. The current findings extend theoretical perspectives on the relationship between sexual satisfaction and suggest that both causal paths be considered in future research and clinical practice

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. US National Institutes of Health and Operation Warp Spee